Celtaxsys Inc. is already prepping the design of a phase III program for acebilustat after the oral leukotriene A4 hydrolase (LTA4H) inhibitor met with success in a phase II effort targeting treatment of cystic fibrosis (CF), irrespective of the causative genotype.